Literature DB >> 23581476

Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions.

L V Fretwell1, J Woolard.   

Abstract

BACKGROUND AND
PURPOSE: Retigabine is a recently approved antiepileptic agent which activates Kv7.2-7.5 potassium channels. It is emerging that these channels have an important role in vascular regulation, but the vascular effects of retigabine in the conscious state are unknown. Hence, in the present study we assessed the regional haemodynamic responses to retigabine in conscious rats. EXPERIMENTAL APPROACH: Male Sprague Dawley rats were chronically instrumented with pulsed Doppler flow probes to measure regional haemodynamic responses to retigabine under control conditions and during acute hypertension induced by infusion of angiotensin II and arginine vasopressin. Further experiments were performed, using the β-adrenoceptor antagonists CGP 20712A, ICI 118551 and propranolol, to elucidate the roles of β-adrenoceptors in the responses to retigabine in vivo and in vitro. KEY
RESULTS: Under normotensive conditions, retigabine induced dose-dependent hypotension and hindquarters vasodilatation, with small, transient renal and mesenteric vasodilatations. In the acutely hypertensive state, the renal and mesenteric, but not hindquarters, vasodilatations were enhanced. The response of the hindquarters vascular bed to retigabine was mediated, in part, by β₂-adrenoceptors. However, in vitro experiments confirmed that retigabine did not act as a β-adrenoceptor agonist. CONCLUSIONS AND IMPLICATIONS: We demonstrated that retigabine causes regionally specific vasodilatations, which are different under normotensive and hypertensive conditions, and are, in part, mediated by β₂-adrenoceptors in some vascular beds but not in others. These results broadly support previous findings and further indicate that Kv7 channels are a potential therapeutic target for the treatment of vascular diseases associated with inappropriate vasoconstriction.
© 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581476      PMCID: PMC3831708          DOI: 10.1111/bph.12203

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission.

Authors:  James F Otto; Matthew M Kimball; Karen S Wilcox
Journal:  Mol Pharmacol       Date:  2002-04       Impact factor: 4.436

2.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

Review 3.  The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.

Authors:  Neil Brickel; Paul Gandhi; Kevan VanLandingham; Janet Hammond; Sarah DeRossett
Journal:  Epilepsia       Date:  2012-03-16       Impact factor: 5.864

4.  Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells.

Authors:  Shuk Yin M Yeung; Iain A Greenwood
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

5.  Reduced KCNQ4-encoded voltage-dependent potassium channel activity underlies impaired β-adrenoceptor-mediated relaxation of renal arteries in hypertension.

Authors:  Preet S Chadha; Friederike Zunke; Hai-Lei Zhu; Alison J Davis; Thomas A Jepps; Søren P Olesen; William C Cole; James D Moffatt; Iain A Greenwood
Journal:  Hypertension       Date:  2012-02-21       Impact factor: 10.190

6.  Regional and temporal changes in cardiovascular responses to norepinephrine and vasopressin during continuous infusion of lipopolysaccharide in conscious rats.

Authors:  T Bennett; R P Mahajan; J E March; P A Kemp; S M Gardiner
Journal:  Br J Anaesth       Date:  2004-06-25       Impact factor: 9.166

7.  Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.

Authors:  W-S Vanessa Ho; Sheila M Gardiner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

8.  Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.

Authors:  S Y M Yeung; V Pucovský; J D Moffatt; L Saldanha; M Schwake; S Ohya; I A Greenwood
Journal:  Br J Pharmacol       Date:  2007-05-21       Impact factor: 8.739

9.  Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension.

Authors:  I Morecroft; A Murray; M Nilsen; A M Gurney; M R MacLean
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

10.  Role of KCNQ channels in skeletal muscle arteries and periadventitial vascular dysfunction.

Authors:  Olga Zavaritskaya; Nadezda Zhuravleva; Johanna Schleifenbaum; Torsten Gloe; Lena Devermann; Reinhart Kluge; Mitko Mladenov; Manfred Frey; Hristo Gagov; Gabor Fésüs; Maik Gollasch; Rudolf Schubert
Journal:  Hypertension       Date:  2012-11-26       Impact factor: 10.190

View more
  3 in total

1.  Impaired Kv7 channel activity in the central amygdala contributes to elevated sympathetic outflow in hypertension.

Authors:  Zhao-Fu Sheng; Hua Zhang; PeiRu Zheng; Shanyan Chen; Zezong Gu; Jing-Jing Zhou; Jeffery G Phaup; Hui-Ming Chang; Edward T H Yeh; Hui-Lin Pan; De-Pei Li
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 13.081

2.  Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.

Authors:  Joanne J Carter; Laurice V Fretwell; Jeanette Woolard
Journal:  FASEB J       Date:  2016-12-16       Impact factor: 5.191

3.  Kv7 voltage-activated potassium channel inhibitors reduce fluid resuscitation requirements after hemorrhagic shock in rats.

Authors:  Sean P Nassoiy; Kenneth L Byron; Matthias Majetschak
Journal:  J Biomed Sci       Date:  2017-01-17       Impact factor: 8.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.